<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="EUR" hierarchy="1" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="http://iatistandard.org/203/schema/downloads/iati-activities-schema.xsd">
  <iati-identifier>NL-KVK-41207989-P-11118-2014014 - 2S4KN</iati-identifier>
  <reporting-org ref="NL-KVK-41207989" type="21">
   <narrative xml:lang="EN">Aidsfonds - Soaaids Nederland</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Langerhans cell antiviral mechanisms control HIV</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="EN">AMC researcher, Theo Geijtenbeek, previously discovered that certain immune cells, so-called Langerhans cells, can destroy the HIV virus. The effectiveness of these cells, however, differs from person to person. Some women, for example, appear more susceptible to HIV than others. This research project aims to determine which factors play a role in destroying HIV.</narrative>
  </description>
  <description type="3">
   <narrative xml:lang="EN">Scientific community</narrative>
  </description>
  <description type="2">
   <narrative xml:lang="EN">The aim of this proposal is to investigate the regulation of these HIV-1 restriction mechanisms in human primary LCs, their in vivo relevance and how immune activation by vaginal microbiota might enhance HIV-1 infection.
This proposal will not only provide novel insights into the mechanism of sexual transmission but will also address the in vivo relevance of the innovative HIV-1 restriction mechanisms as well as LCs in HIV-1
susceptibility.
The expected results will identify molecular targets for intervention, allow identification of more susceptible patient groups and provide novel preventive strategies to combat HIV-1 susceptibility. Thereby limiting HIV infection and transmission.</narrative>
  </description>
  <description type="4">
   <narrative xml:lang="EN">The main route of HIV-1 infection is sexual transmission across mucosal genital tissues. Langerhans cells (LCs) reside in mucosal vagina and foreskin epithelium, and are therefore the first immune cells to encounter HIV-1 upon sexual transmission.</narrative>
  </description>
  <participating-org ref="NL-KVK-34362777" role="4" type="80">
   <narrative xml:lang="EN">AMC - Experimentele immunologie</narrative>
  </participating-org>
  <participating-org ref="NL-KVK-41207989" role="1" type="22">
   <narrative xml:lang="EN">Aidsfonds Grants</narrative>
  </participating-org>
  <participating-org ref="NL-KVK-41207989" role="2" type="22">
   <narrative xml:lang="EN">Aidsfonds</narrative>
  </participating-org>
  <activity-status code="4"></activity-status>
  <activity-date iso-date="2014-11-30" type="1"></activity-date>
  <activity-date iso-date="2018-11-30" type="3"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">Aidsfonds - Soaaids Nederland</narrative>
   </organisation>
   <telephone>+31(0)206262669</telephone>
   <email>IATI@aidsfonds.nl</email>
  </contact-info>
  <sector code="13040" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Langerhans cell antiviral mechanisms control HIV STD control including HIV/AIDS</narrative>
  </sector>
  <policy-marker code="9" significance="1" vocabulary="1"></policy-marker>
  <collaboration-type code="3"></collaboration-type>
  <default-flow-type code="30"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="C01" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget status="1" type="1">
   <period-start iso-date="2014-11-30"></period-start>
   <period-end iso-date="2018-11-30"></period-end>
   <value currency="EUR" value-date="2014-11-30">250000</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2015-12-30"></transaction-date>
   <value currency="EUR" value-date="2015-12-30">100000</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014014, kpl</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Experimentele immunologie</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2015-12-30"></transaction-date>
   <value currency="EUR" value-date="2015-12-30">100000</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014014, kpl</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Experimentele immunologie</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2016-11-27"></transaction-date>
   <value currency="EUR" value-date="2016-11-27">50000</value>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Experimentele immunologie</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2016-11-27"></transaction-date>
   <value currency="EUR" value-date="2016-11-27">50000</value>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Experimentele immunologie</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2017-11-27"></transaction-date>
   <value currency="EUR" value-date="2017-11-27">50000</value>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Experimentele immunologie</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2017-11-27"></transaction-date>
   <value currency="EUR" value-date="2017-11-27">50000</value>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Experimentele immunologie</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2020-01-28"></transaction-date>
   <value currency="EUR" value-date="2020-01-28">46196</value>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Experimentele immunologie</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-01-28"></transaction-date>
   <value currency="EUR" value-date="2020-01-28">46196</value>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Experimentele immunologie</narrative>
   </receiver-org>
  </transaction>
 </iati-activity>
</iati-activities>
